David McKinley actually said...

We need a robust biopharma industry, and I think everyone agrees to that, investing in rare diseases.

Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-...

H.R. 3, unfortunately, is an overreach, and unfortunately it gives me the impression, for those in the package, that Congress is seemingly w...

The status quo is not acceptable. Congress must act to ensure that the American people have access to and can afford the treatments that the...